BioCryst Pharmaceuticals Inc (BCRX) — Analysis Summary
BioCryst Pharmaceuticals Inc (BCRX) has a market cap of $2.26B with year-over-year revenue growth of +94.1%. Net margin stands at 30.2%. The stock trades at a P/E ratio of -4.9.
Key Takeaways
- Revenue changed +94.1% year-over-year
- Net margin of 30.2%
- P/E ratio of -4.9
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, BCRX posted revenue growth of +94.1% and trades at a P/E of -4.9.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.